# Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)

> **NCT02633644** · PHASE2 · TERMINATED · sponsor: **Enopace Biomedical** · enrollment: 30 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DEVICE:** Harmony System

## Key facts

- **NCT ID:** NCT02633644
- **Lead sponsor:** Enopace Biomedical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2023-06
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** The company shut down
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633644, "Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02633644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*